Background: Neurodegenerative diseases primarily afflict the elderly and are characterized by a progressive loss of neurons. Oxidative stress is intricately linked to the advancement of these conditions. This study focuses on Phoenix dactylifera (P. dactylifera; Family: Arecaceae), commonly known as “Ajwa,” a globally cultivated herbal plant renowned for its potent antioxidant properties and reported neuroprotective effects in pharmacological studies. Method: This comprehensive systematic review delves into the antioxidant properties of plant extracts and their phytochemical components, with a particular emphasis on P. dactylifera and its potential neuroprotective benefits. Preferred reporting items for systemic reviews and meta-analysis (PRISMA) were employed to review the articles. Results: The study includes 269 articles published in the literature and 17 were selected after qualitative analysis. The growing body of research underscores the critical role of polyphenolic compounds found in P. dactylifera, which significantly contribute to its neuroprotective effects through antioxidant mechanisms. Despite emerging insights into the antioxidant actions of P. dactylifera, further investigation is essential to fully elucidate the specific pathways through which it confers neuroprotection. Conclusions: Like many other plant-based supplements, P. dactylifera’s antioxidant effects are likely mediated by synergistic interactions among its diverse bioactive compounds, rather than by any single constituent alone. Therefore, additional preclinical and clinical studies are necessary to explore P. dactylifera’s therapeutic potential comprehensively, especially in terms of its targeted antioxidant activities aimed at mitigating neurodegenerative processes. Such research holds promise for advancing our understanding and potentially harnessing the therapeutic benefits of P. dactylifera in neuroprotection.
Background: Down syndrome (DS) is one of the most prevalent chromosomal abnormalities affecting global healthcare. Recent advances in artificial intelligence (AI) and machine learning (ML) have enhanced DS diagnostic accuracy. However, there is a lack of thorough evaluations analyzing the overall impact and effectiveness of AI-based DS diagnostic approaches. Objectives: This review intends to identify methodologies and technologies used in AI-driven DS diagnostics. It evaluates the performance of AI models in terms of standard evaluation metrics, highlighting their strengths and limitations. Methodology: In order to ensure transparency and rigor, the authors followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. They extracted 1175 articles from major academic databases. By leveraging inclusion and exclusion criteria, a final set of 25 articles was selected. Outcomes: The findings revealed significant advancements in AI-powered DS diagnostics across diverse data modalities. The modalities, including facial images, ultrasound scans, and genetic data, demonstrated strong potential for early DS diagnosis. Despite these advancements, this review outlined the limitations of AI approaches. Small and imbalanced datasets reduce the generalizability of the AI models. The authors present actionable strategies to enhance the clinical adoptions of these models.
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition, contributing significantly to global morbidity and mortality. Traditional diagnostic tools are effective in diagnosing COPD. However, these tools demand specialized equipment and expertise. Advances in artificial intelligence (AI) provide a platform for enhancing COPD diagnosis by leveraging diverse data modalities. The existing reviews primarily focus on single modalities and lack information on interpretability and explainability. Thus, this review intends to synthesize the AI-powered frameworks for COPD identification, focusing on data modalities, methodological innovation, evaluation strategies, and reporting limitations and potential biases. By adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic search was conducted across multiple repositories. From an initial pool of 1978 records, 22 studies were included in this review. The included studies demonstrated exceptional performance in specific settings. Most studies were retrospective and limited in diversity, lacking generalizability and external or prospective validation. This review presents a roadmap for advancing AI-assisted COPD detection. By highlighting the strengths and limitations of existing studies, it supports the development of future research. Future studies can utilize the findings to build models using prospective, multicenter, and multi-ethnic validations, ensuring generalizability and fairness.
A multifunctional nanocarrier of lactoferrin-functionalized Pluronic F-127 capped dopamine-loaded mesoporous silica nanocomposite (Lf-DA-MSN-PF127), was designed for targeted drug delivery across the blood–brain barrier (BBB) via intranasal.
Background: Polypharmacy and potential drug-drug interactions (pDDIs) are major challenges in the management of elderly patients with multiple comorbidities, often leading to adverse drug events and increased healthcare burden. Aim: This study aimed to determine the prevalence and patterns of polypharmacy and pDDIs among elderly patients attending Yenepoya Medical College and Hospital, Mangalore, India. Methods: A cross-sectional study was conducted from January to June 2023 among 310 elderly patients (aged ≥60 years) selected through simple random sampling from both in-patient and out-patient departments. Polypharmacy was defined as the concurrent use of ≥5 medications, and excessive polypharmacy as ≥9 medications. Drug interaction screening was performed using UpToDate and Medscape interaction checker tools. Statistical analyses included descriptive statistics, t-tests, chi-square tests, and regression analysis, with significance set at p < 0.05. Results: The prevalence of polypharmacy was slightly higher in females (53.84%) than males (51.94%), with the highest rates observed in the 70–79 age group (48.88%). Most patients experienced moderate (50%) drug interactions. A significant gender difference was observed in the number of drugs prescribed at treatment ( p = 0.0032), but not at discharge. Regression analysis identified gender ( p = 0.018) and inpatient status ( p < 0.001) as significant predictors of polypharmacy, while age was not ( p = 0.719). Conclusion: This study reveals a high prevalence of polypharmacy among elderly patients attending Yenepoya Medical College and Hospital. Polypharmacy was found to be more prevalent among female patients, older age groups, and in inpatient wards. The distribution of drug interactions revealed a pervasive nature across various degrees, with moderate interactions being the most common. Future research should use larger samples, and diverse populations to better understand polypharmacy, drug interactions, and outcomes.
Down syndrome (DS) is one of the prevalent chromosomal disorders, representing distinctive craniofacial features and a range of developmental and medical challenges. Due to the lack of clinical expertise and high infrastructure costs, access to genetic testing is restricted to resource-constrained clinical settings. There is a demand for developing a non-invasive and equitable DS screening tool, facilitating DS diagnosis for a wide range of populations. In this study, we develop and validate a robust, interpretable deep learning model for the early detection of DS using facial images of infants. A hybrid feature extraction architecture combining RegNet X–MobileNet V3 and vision transformer (ViT)-Linformer is developed for effective feature representation. We use an adaptive attention-based feature fusion to enhance the proposed model’s focus on diagnostically relevant facial regions. Bayesian optimization with hyperband (BOHB) fine-tuned extremely randomized trees (ExtraTrees) is employed to classify the features. To ensure the model’s generalizability, stratified five-fold cross-validation is performed. Compared to the recent DS classification approaches, the proposed model demonstrates outstanding performance, achieving an accuracy of 99.10%, precision of 98.80%, recall of 98.87%, F1-score of 98.83%, and specificity of 98.81%, on the unseen data. The findings underscore the strengths of the proposed model as a reliable screening tool to identify DS in the early stages using the facial images. This study paves the foundation to build equitable, scalable, and trustworthy digital solution for effective pediatric care across the globe.